Modifying dysfunctional beliefs in social anxiety disorder with an emotion-focused approach-avoidance modification training - a pilot study.

J Behav Ther Exp PsychiatryApr 19, 2026 (epub)
Clinical ResearchPsychiatry

Hannah Streit, Lena Merkt, Marie Reindl et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled pilot study evaluated the feasibility and therapeutic potential of an emotion-focused approach-avoidance modification training (eAAMT) for social anxiety disorder (SAD) in 30 participants. The results indicated that those receiving eAAMT-SAD experienced a greater reduction in anxiety symptoms compared to control groups, with effect sizes of g = 0.42 and g = 0.39 for pre-post comparisons.

Key findings

  • Participants in the eAAMT-SAD condition showed a greater reduction in anxiety symptoms compared to the non-active control group.
  • Effect size for anxiety reduction in the eAAMT-SAD group was g = 0.42 compared to the non-active control.
  • Follow-up results indicated a sustained reduction in anxiety symptoms with an effect size of g = 0.56 for the non-active control group.

Why it matters

Understanding and modifying dysfunctional beliefs in social anxiety disorder can enhance treatment outcomes. This study suggests that eAAMT may be a promising intervention to reduce anxiety symptoms, warranting further investigation.

Source

Published in J Behav Ther Exp Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.